It's been quite a rollercoaster six weeks for old-line pharmaceutical company Merck, based in New Jersey. As September ended, the company announced the voluntary withdrawal of its blockbuster anti-arthritis COX-2 inhibitor drug, Vioxx, due to cardiovascular toxicity. Subsequently, Merck has been embroiled in charges of a cover-up involving what they knew about Vioxx's side effects and when they knew it. The company faces legions of litigants led by tort-lawyer centurions, while TV and newspaper ads implore those "injured by Vioxx" to call for a free consultation.
It's been quite a rollercoaster six weeks for old-line pharmaceutical company Merck, based in New Jersey. As September ended, the company announced the voluntary withdrawal of its blockbuster anti-arthritis COX-2 inhibitor drug, Vioxx, due to cardiovascular toxicity. Subsequently, Merck has been embroiled in charges of a cover-up involving what they knew about Vioxx's side effects and when they knew it. The company faces legions of litigants led by tort-lawyer centurions, while TV and newspaper ads implore those "injured by Vioxx" to call for a free consultation.